Nintedanib in non-small cell lung cancer: From preclinical to approval

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 4, 2015, Pages 164-172

  Caglevic, Christian ^a   Grassi, Massimiliano ^b   Raez, Luis ^c   Listi, Angela ^d   Giallombardo, Marco ^b,d   Bustamante, Eva ^a   Gil Bazo, Ignacio ^e   Rolfo, Christian ^b  

^a Centro Oncológico Fundación Arturo López Pérez   (Chile)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Memorial Health Care System   (United States)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

antiangiogenic drugs; BIBF1120; nintedanib; non small cell lung cancer; NSCLC; tyrosine kinase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FIBROBLAST GROWTH FACTOR; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; MOTESANIB; NINTEDANIB; PACLITAXEL; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CAPILLARY DENSITY; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONFUSION; DECREASED APPETITE; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ESOPHAGUS PAIN; FATIGUE; FEBRILE NEUTROPENIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LUNG EMBOLISM; LUNG HEMORRHAGE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PERICYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; RASH; RESPIRATORY FAILURE; REVIEW; SEPSIS; STOMACH CANCER; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING; ADENOCARCINOMA; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PRECLINICAL STUDY;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84937032951     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815579608     Document Type: Review

References (28)

1. Ahn J Lee K Sun J Park K Kang E Cho E. (2013) A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer 82: 455–460.
2. Aisner J Manola J Dakhil S Stella P Sovak M Schiller J (2013) Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501). J Thoracic Oncol 8: 1075–1083.
3. Andrae J Gallini R Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Develop 22: 1276–1312.
4. Boutsikou E Kontakiotis T Zarogoulidis P Darwiche K Eleptheriadou E Porpodis K. (2013) Docetaxel–carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Target Ther 6: 125–134.
5. Cao R Ji H Feng N Zhang Y Yang X Andersson P Sun Y. (2012) Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA 109: 15894–15899.
6. Cenik B Ostapoff K Gerber D Brekken R (2013) BIBF1120 (Nintedanib, a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Therapeut 12: 992–1001.
7. Doebele R Conkling P Traynor A Otterson G Zhao Y Wind S. (2012) A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 23: 2094–2102.
8. Ellis P Kaiser R Zhao Y Stopfer P Gyorffy S Hanna N (2010) Phase I open-label study of continuous treatment with BIBF1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 16: 2881–2889.
9. Garon E Ciuleanu T Arrieta O Prabhash K Syrigos K Goksel T. (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384: 665–673.
10. Groen H Socinski M Grossi F Juhasz E Gridelli C Baas P. (2013) A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol 24: 2382–2389.
11. Hanna N Kaiser R Sullivan R Aren O Ahn M Tiangco B. (2013) Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 31(Suppl.): abstract 8034.
12. Heist R Wang X Hodgson L Otterson G Stinchcombe T Gandhi L. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thoracic Oncol 9: 214–221.
13. Hilberg F Roth G Krssak M Kautschitsch S Sommergruber W Tontsch-Grunt U. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774–4782.
14. Holmes K Roberts O Thomas A Cross M (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003–2012.
15. Kubota K Ichinose Y Scagliotti G Spigel D Kim J Shinkai T. (2014) Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Ann Oncol 25: 529–536.
16. Mross K Stefanic M Gmehling D Frost A Baas F Unger C. (2010) Phase I study of the angiogenesis Inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16: 311–319.
17. Niho S Kunitoh H Nokihara H Horai T Ichinose Y Hida T. (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76: 362–367.
18. Nishida N Yano H Nishida T Kamura T Kojiro M (2006) Angiogenesis in cancer. Vasc Health Risk Manage 2: 213–219.
19. Onimaru M Yonemitsu Y (2011) Angiogenic and lymphangiogenic cascades in the tumor microenvironment. Front Biosci 3: 216–225.
20. Paz-Ares L Biesma B Heigener D von Pawel J Eisen T Bennouna J. (2012) Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, non squamous non-small-cell lung cancer. J Clin Oncol 30: 3084–3092.
21. Reck M Kaiser R Eschbach C Stefanic M Love J Gatzemeier U. (2011) A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 22: 1374–1381.
22. Reck M Kaiser R Mellemgaard A Douillard J Orlov S Krzakowski M. (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15: 143–155.
23. Reck M von Pawel J Zatloukal P Ramlau R Gorbounova V Hirsh V. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227–1234.
24. Rolfo C Raez L Bronte G Santos E Papadimitriou K Buffoni L. (2013) BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Exp Opin Invest Drugs 22: 1081–1088.
25. Scagliotti G Vynnychenko I Park K Ichinose Y Kubota K Blackhall F. (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30: 2829–2836.
26. Stopfer P Rathgen K Bischoff D Lüdtke S Marzin K Kaiser R. (2011) Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41: 297–311.
27. Torti D Trusolino L (2011) Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 3: 623–636.
28. Wakelee H Lee J Hanna N Traynor A Carbone D Schiller J. (2012) A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thoracic Oncol 7: 1574–1582.